---
document_datetime: 2025-12-02 06:10:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/farydak.html
document_name: farydak.html
version: success
processing_time: 0.118974
conversion_datetime: 2025-12-26 20:00:29.786945
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Farydak

[RSS](/en/individual-human-medicine.xml/66369)

##### Authorised

This medicine is authorised for use in the European Union

panobinostat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Farydak](#news-on)
- [Preventing medication errors](#preventing-medication-errors-1290)
- [More information on Farydak](#-more-information-on-farydak-79276)
- [More information on Farydak](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Farydak. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Farydak.

For practical information about using Farydak, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Farydak and what is it used for?

Farydak is a cancer medicine used in combination with two other medicines, bortezomib and dexamethasone, to treat multiple myeloma (a cancer of the bone marrow). It is given to adults whose disease has come back or got worse after at least two previous treatments, including bortezomib and an immunomodulatory medicine (a medicine that acts on the immune system).

Farydak contains the active substance panobinostat.

Because the number of patients with multiple myeloma is low, the disease is considered 'rare', and Farydak was designated an 'orphan medicine' (a medicine used in rare diseases) on 8 November 2012.

## How is Farydak used?

Treatment with Farydak must be started by a doctor experienced in the treatment of cancer and the medicine can only be obtained with a prescription.

Farydak is available as capsules (10, 15 and 20 mg) and it is given in 21-day treatment cycles, together with bortezomib and dexamethasone. The recommended starting dose of Farydak is 20 mg, taken on days 1, 3, 5, 8, 10 and 12 of the cycle. Patients are given the medicine for 8 cycles, and further 8 cycles of treatment are recommended in those that benefit. The doctor may have to adjust or delay the dose in patients who experience severe side effects. For further information, see the summary of product characteristics (part of the product information).

## How does Farydak work?

The active substance in Farydak, panobinostat, is a type of medicine called a histone deacetylase (HDAC) inhibitor. It blocks the activity of enzymes called histone deacetylases (HDACs), which are involved in switching the activity of genes on and off within cells. In multiple myeloma, panobinostat is expected to keep genes that suppress the division and growth of the cancer cells switched 'on'. This is expected to stop the cancer cells from multiplying and to activate processes that kill the cell, thereby slowing down the growth of the cancer.

## What benefits of Farydak have been shown in studies?

The benefits of Farydak have been shown in one main study involving 768 patients with multiple myeloma that had come back after previous treatments. The medicine was compared with placebo (a dummy treatment) as an addition to treatment with bortezomib and dexamethasone. The main measure of effectiveness was the average length of time before the patient's disease got worse again (progression-free survival), which was 12 months in patients given Farydak, compared with around 8 months in those given placebo.

When results were analysed just for the group of patients who had previously received at least two previous treatments, including bortezomib and an immunomodulatory medicine (thalidomide, lenalidomide or pomalidomide), the average time until the myeloma got worse was 12.5 months with Farydak, versus 4.7 months with placebo.

## What are the risks associated with Farydak?

The most common side effects with Farydak (which may affect more than 1 in 10 people) are diarrhoea, tiredness, nausea (feeling sick) and vomiting, and effects on the blood such as thrombocytopenia (low levels of blood platelets which are important for blood clotting), anaemia and neutropenia and lymphopenia (low levels of certain white blood cells). The most significant effects that led to patients having to stop treatment (which happened in about 4 patients in 10) were diarrhoea, weakness and tiredness, and pneumonia (lung infection). Effects on the heart occurred in between 1 and 2 patients in 10 and included tachycardia (increased heart rate), palpitations, and irregular heart rhythms (atrial fibrillation, sinus tachycardia); more rarely patients had changes in electrical conduction in the heart (prolonged QTc interval). For the full list of all side effects reported with Farydak, see the package leaflet.

Farydak must not be used in women who are breast-feeding. For the full list of restrictions, see the package leaflet.

## Why is Farydak approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) considered the increase in progression free survival to be clinically significant although it noted that a benefit in overall survival had not yet been shown. In addition, panobinostat works in a different way to existing treatments. This means that for patients who have previously received at least two previous treatments, including bortezomib and immunomodulatory agents, who have limited treatment options and therefore a high unmet medical need, it offers a new alternative. Although the side effects were of concern and could not be justified in patients who could be given less toxic treatments, the CHMP considered that they were acceptable in this previously treated subgroup in view of the lack of alternatives, and could be managed. The CHMP therefore decided that Farydak's benefits are greater than its risks in this group and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Farydak?

A risk management plan has been developed to ensure that Farydak is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Farydak, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company that markets Farydak will provide educational materials for patients, including a patient card, to help them take the medicine correctly. It will also provide a final analysis from the main study on how long patients who have been treated with the medicine survive.

Further information can be found in the [Farydak : EPAR - Risk management plan](/en/documents/rmp/farydak-epar-risk-management-plan_en.pdf) .

## Other information about Farydak

The European Commission granted a marketing authorisation valid throughout the European Union for Farydak on 28 August 2015.

For more information about treatment with Farydak, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Farydak : EPAR - Summary for the public

English (EN) (78.67 KB - PDF)

**First published:** 11/09/2015

**Last updated:** 11/09/2015

[View](/en/documents/overview/farydak-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-386)

български (BG) (106.28 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/bg/documents/overview/farydak-epar-summary-public_bg.pdf)

español (ES) (77.42 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/es/documents/overview/farydak-epar-summary-public_es.pdf)

čeština (CS) (104.8 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/cs/documents/overview/farydak-epar-summary-public_cs.pdf)

dansk (DA) (76.77 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/da/documents/overview/farydak-epar-summary-public_da.pdf)

Deutsch (DE) (79.08 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/de/documents/overview/farydak-epar-summary-public_de.pdf)

eesti keel (ET) (75.98 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/et/documents/overview/farydak-epar-summary-public_et.pdf)

ελληνικά (EL) (107.56 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/el/documents/overview/farydak-epar-summary-public_el.pdf)

français (FR) (78.2 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/fr/documents/overview/farydak-epar-summary-public_fr.pdf)

hrvatski (HR) (99.27 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/hr/documents/overview/farydak-epar-summary-public_hr.pdf)

italiano (IT) (76.76 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/it/documents/overview/farydak-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.46 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/lv/documents/overview/farydak-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (103.47 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/lt/documents/overview/farydak-epar-summary-public_lt.pdf)

magyar (HU) (99.91 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/hu/documents/overview/farydak-epar-summary-public_hu.pdf)

Malti (MT) (105.34 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/mt/documents/overview/farydak-epar-summary-public_mt.pdf)

Nederlands (NL) (77.18 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/nl/documents/overview/farydak-epar-summary-public_nl.pdf)

polski (PL) (104.3 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/pl/documents/overview/farydak-epar-summary-public_pl.pdf)

português (PT) (77.26 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/pt/documents/overview/farydak-epar-summary-public_pt.pdf)

română (RO) (101.57 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/ro/documents/overview/farydak-epar-summary-public_ro.pdf)

slovenčina (SK) (103.59 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/sk/documents/overview/farydak-epar-summary-public_sk.pdf)

slovenščina (SL) (97.64 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/sl/documents/overview/farydak-epar-summary-public_sl.pdf)

Suomi (FI) (76.57 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/fi/documents/overview/farydak-epar-summary-public_fi.pdf)

svenska (SV) (76.95 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/sv/documents/overview/farydak-epar-summary-public_sv.pdf)

Farydak : EPAR - Risk management plan

English (EN) (631.26 KB - PDF)

**First published:** 01/10/2025

[View](/en/documents/rmp/farydak-epar-risk-management-plan_en.pdf)

## Product information

Farydak : EPAR - Product Information

English (EN) (439.21 KB - PDF)

**First published:** 11/09/2015

**Last updated:** 01/10/2025

[View](/en/documents/product-information/farydak-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-135)

български (BG) (588.13 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/bg/documents/product-information/farydak-epar-product-information_bg.pdf)

español (ES) (423.54 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/es/documents/product-information/farydak-epar-product-information_es.pdf)

dansk (DA) (443.24 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/da/documents/product-information/farydak-epar-product-information_da.pdf)

Deutsch (DE) (419.82 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/de/documents/product-information/farydak-epar-product-information_de.pdf)

eesti keel (ET) (415.56 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/et/documents/product-information/farydak-epar-product-information_et.pdf)

ελληνικά (EL) (570.73 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/el/documents/product-information/farydak-epar-product-information_el.pdf)

français (FR) (426 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/fr/documents/product-information/farydak-epar-product-information_fr.pdf)

hrvatski (HR) (483.46 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/hr/documents/product-information/farydak-epar-product-information_hr.pdf)

íslenska (IS) (392.92 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/is/documents/product-information/farydak-epar-product-information_is.pdf)

italiano (IT) (424.47 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/it/documents/product-information/farydak-epar-product-information_it.pdf)

latviešu valoda (LV) (536.43 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/lv/documents/product-information/farydak-epar-product-information_lv.pdf)

lietuvių kalba (LT) (544.78 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/lt/documents/product-information/farydak-epar-product-information_lt.pdf)

magyar (HU) (511.9 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/hu/documents/product-information/farydak-epar-product-information_hu.pdf)

Malti (MT) (644.98 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/mt/documents/product-information/farydak-epar-product-information_mt.pdf)

Nederlands (NL) (407.01 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/nl/documents/product-information/farydak-epar-product-information_nl.pdf)

norsk (NO) (399.29 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/no/documents/product-information/farydak-epar-product-information_no.pdf)

polski (PL) (559.99 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/pl/documents/product-information/farydak-epar-product-information_pl.pdf)

português (PT) (404.19 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/pt/documents/product-information/farydak-epar-product-information_pt.pdf)

română (RO) (586.38 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/ro/documents/product-information/farydak-epar-product-information_ro.pdf)

slovenčina (SK) (545.71 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/sk/documents/product-information/farydak-epar-product-information_sk.pdf)

slovenščina (SL) (512.39 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/sl/documents/product-information/farydak-epar-product-information_sl.pdf)

Suomi (FI) (398.73 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/fi/documents/product-information/farydak-epar-product-information_fi.pdf)

svenska (SV) (413.89 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

01/10/2025

[View](/sv/documents/product-information/farydak-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0030 28/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Farydak : EPAR - All Authorised presentations

English (EN) (165.41 KB - PDF)

**First published:** 11/09/2015

**Last updated:** 11/09/2015

[View](/en/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-88)

български (BG) (173.39 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/bg/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_bg.pdf)

español (ES) (167.67 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/es/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_es.pdf)

čeština (CS) (170.04 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/cs/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (167.66 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/da/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (167.61 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/de/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (167.14 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/et/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (172.82 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/el/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_el.pdf)

français (FR) (166.91 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/fr/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (167.69 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/hr/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (166.02 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/is/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_is.pdf)

italiano (IT) (165.42 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/it/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (170.45 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/lv/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (171.21 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/lt/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (169.29 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/hu/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (171.11 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/mt/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (166.79 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/nl/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (166.46 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/no/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_no.pdf)

polski (PL) (115.96 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/pl/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_pl.pdf)

português (PT) (166.36 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/pt/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_pt.pdf)

română (RO) (169.31 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/ro/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (171.88 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/sk/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (167.58 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/sl/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (166.58 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/fi/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (166.33 KB - PDF)

**First published:**

11/09/2015

**Last updated:**

11/09/2015

[View](/sv/documents/all-authorised-presentations/farydak-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Farydak Active substance panobinostat lactate anhydrous International non-proprietary name (INN) or common name panobinostat Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01XH03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.

Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.

## Authorisation details

EMA product number EMEA/H/C/003725 Marketing authorisation holder

pharmaand GmbH

Taborstrasse 1

Opinion adopted 25/06/2015 Marketing authorisation issued 28/08/2015 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Farydak : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (195.51 KB - PDF)

**First published:** 13/04/2016

**Last updated:** 01/10/2025

[View](/en/documents/procedural-steps-after/farydak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Farydak-H-C-PSUSA-10409-201908 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/318994/2020

English (EN) (137.78 KB - PDF)

**First published:** 16/06/2020

[View](/en/documents/scientific-conclusion/farydak-h-c-psusa-10409-201908-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Farydak-H-C-PSUSA-10409-201608 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/425022/2017

English (EN) (70.63 KB - PDF)

**First published:** 05/07/2017

**Last updated:** 05/07/2017

[View](/en/documents/scientific-conclusion/farydak-h-c-psusa-10409-201608-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Farydak : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/496296/2015 Rev. 1

English (EN) (6.62 MB - PDF)

**First published:** 11/09/2015

**Last updated:** 11/09/2015

[View](/en/documents/assessment-report/farydak-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Farydak

Adopted

Reference Number: EMA/CHMP/304387/2015

English (EN) (67.03 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 26/06/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-farydak_en.pdf)

#### News on Farydak

[First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU](/en/news/first-hdac-inhibitor-treatment-multiple-myeloma-recommended-approval-eu) 26/06/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

#### Preventing medication errors

Farydak: compliance card to be given to patients to ensure correct use and avoid medication errors

Reference Number: EMA/599292/2015

English (EN) (107.75 KB - PDF)

**First published:** 27/11/2015

[View](/en/documents/medication-error/farydak-compliance-card-be-given-patients-ensure-correct-use-avoid-medication-errors_en.pdf)

#### More information on Farydak

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-12-1063) on 8 November 2012. Farydak was withdrawn from the Community register of orphan medicinal products in September 2025 at the end of the 10-year period of market exclusivity.

#### More information on Farydak

- [Panobinostat Post Authorization Safety Study, a non-interventional study of panobinostat in combination with bortezomib and dexamethasone in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) - post-authorisation study](https://catalogues.ema.europa.eu/study/34837)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/10/2025

## Share this page

[Back to top](#main-content)